[A20-118] Nivolumab (non-small cell lung cancer, combination with ipilimumab) - Benefit assessment according to §35a Social Code Book V
Last updated 04.06.2021
Commission awarded on 14.12.2020 by the Federal Joint Committee (G-BA).
First-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitizing EGFR mutation or ALK translocation
PD-L1 expression (TPS) of at least 50 percent: added benefit not proven.
PD-L1 expression (TPS) below 50 percent: non-squamous histology: indication of added benefit; extent “non-quantifiable". Squamous histology: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.